Real-world outcomes in patients with AML and MDS treated with Azacitidine

被引：0
|
作者：
Prusak, E. [1 ]
Lawes, M. [2 ]
Collins, A. [2 ]
机构：
[1] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England
[2] Norfolk & Norwich Univ Hosp, Haematol, Norwich, Norfolk, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷
关键词：
AML; Azacitidine; mds;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH18-PO-0
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [11] Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
    Scott, Bart L.
    Ramakrishnan, Aravind
    Storer, Barry
    Becker, Pamela S.
    Petersdorf, Steve
    Estey, Elihu H.
    Deeg, H. Joachim
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (06) : 944 - 947
  • [12] Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine
    Zeidan, Amer M.
    Bewersdorf, Jan Philipp
    Hasle, Vanessa
    Shallis, Rory M.
    Thompson, Ethan
    de Menezes, Daniel Lopes
    Rose, Shelonidta
    Boss, Isaac
    Halene, Stephanie
    Haferlach, Torsten
    Fox, Brian A.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [13] A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?
    Solana-Altabella, Antonio
    Rodriguez-Veiga, Rebeca
    Martinez-Cuadron, David
    Montesinos, Pau
    ANNALS OF HEMATOLOGY, 2024, : 913 - 935
  • [14] Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy*
    Miyamoto, Toshihiro
    Sanford, David
    Tomuleasa, Ciprian
    Hsiao, Hui-Hua
    Enciso Olivera, Leonardo Jose
    Kumar Enjeti, Anoop
    Gimenez Conca, Alberto
    Bernal Del Castillo, Teresa
    Girshova, Larisa
    Paola Martelli, Maria
    Guvenc, Birol
    Delgado, Alexander
    Duan, Yinghui
    Garbayo Guijarro, Belen
    Llamas, Cynthia
    Lee, Je-Hwan
    LEUKEMIA & LYMPHOMA, 2022, 63 (04) : 928 - 938
  • [15] A single centre experience with azacitidine for MDS, AML and CMML in relation to cytogenetic risk and performance status. Our results suggest azacitidine use in the real world does not replicate AZA-001 overall survival rates and has poorer outcomes
    Page, C.
    Whalley, I.
    Dann, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 41 - 42
  • [16] Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience
    Baba, Yuta
    Hida, Noriko
    Sambe, Takehiko
    Abe, Maasa
    Kabasawa, Nobuyuki
    Sakai, Hirotaka
    Yoshimura, Kiyoshi
    Fukuda, Tetsuya
    ANTICANCER RESEARCH, 2024, 44 (05) : 2003 - 2007
  • [17] Real-World Treatment Patterns and Clinical Outcomes in Romanian Patients With AML Unfit for First-Line Intensive Chemotherapy
    Tomuleasa, Ciprian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S212 - S212
  • [18] Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
    Ong, Shin Yeu
    Yun, Melinda Tan Si
    Halim, Nurul Aidah Abdul
    Christopher, Dheepa
    Jen, Wei Ying
    Gallardo, Christian
    Yim, Angeline Tan Hwee
    Woon, Yeow Kheong
    Ng, Heng Joo
    Ooi, Melissa
    Wong, Gee Chuan
    CANCERS, 2022, 14 (15)
  • [19] No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine-a prospective multicenter study by the Polish Adult Leukemia Group
    Madry, Krzysztof
    Lis, Karol
    Sienkiewicz, Elzbieta
    Drozd-Sokolowska, Joanna
    Biecek, Przemyslaw
    Sosnia, Oktawia
    Golos, Aleksandra
    Olszewska-Szopa, Magdalena
    Obara, Agata
    Walkowiak, Zuzanna
    Sciesinska, Joanna
    Subocz, Edyta
    Butrym, Aleksandra
    Machowicz, Rafal
    Budziszewska, Katarzyna
    Basak, Grzegorz
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [20] Azacitidine resistance caused by LAMP2 deficiency: a therapeutic window for the use of autophagy inhibitors in MDS/AML patients?
    Robert, Guillaume
    Auberger, Patrick
    AUTOPHAGY, 2019, 15 (05) : 927 - 929
12345